CN101945664A - 用α胸腺肽和激酶抑制剂的组合治疗黑素瘤 - Google Patents

用α胸腺肽和激酶抑制剂的组合治疗黑素瘤 Download PDF

Info

Publication number
CN101945664A
CN101945664A CN2008801268138A CN200880126813A CN101945664A CN 101945664 A CN101945664 A CN 101945664A CN 2008801268138 A CN2008801268138 A CN 2008801268138A CN 200880126813 A CN200880126813 A CN 200880126813A CN 101945664 A CN101945664 A CN 101945664A
Authority
CN
China
Prior art keywords
day
melanoma
administration
group
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801268138A
Other languages
English (en)
Chinese (zh)
Inventor
伊斯雷尔·里奥斯
辛西娅·W·塔特希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN101945664A publication Critical patent/CN101945664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801268138A 2007-12-13 2008-12-12 用α胸腺肽和激酶抑制剂的组合治疗黑素瘤 Pending CN101945664A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1347607P 2007-12-13 2007-12-13
US61/013,476 2007-12-13
PCT/US2008/086545 WO2009076587A1 (en) 2007-12-13 2008-12-12 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor

Publications (1)

Publication Number Publication Date
CN101945664A true CN101945664A (zh) 2011-01-12

Family

ID=40755899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801268138A Pending CN101945664A (zh) 2007-12-13 2008-12-12 用α胸腺肽和激酶抑制剂的组合治疗黑素瘤

Country Status (8)

Country Link
US (1) US20100267637A1 (enExample)
EP (1) EP2240194A4 (enExample)
JP (1) JP2011506473A (enExample)
CN (1) CN101945664A (enExample)
AR (1) AR069769A1 (enExample)
AU (1) AU2008335025A1 (enExample)
CA (1) CA2708229A1 (enExample)
WO (1) WO2009076587A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148279A (zh) * 2014-10-21 2017-09-08 赛生制药有限公司 用免疫刺激剂治疗癌症

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRIS H.TAKIMOTO ET AL.: "Safety and anti-tumor activity of sorafernib(Nexavar)in combination with other anti-cancer agents:a review of clinical trials.", 《CANCER CHEMOTHER PHARMACOL》 *
GARACI E ET AL.: "Thymosin alpha 1 in the treatment of cancer:from basic research to clinical application", 《INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY》 *
LOPEZ M ET AL.: "Biochemotherapy with thymosin α1,interleukin-2 and dacarbazine in patients with metastatic melanoma:Clinical and immunological effects.", 《ANNALS OF ONCOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148279A (zh) * 2014-10-21 2017-09-08 赛生制药有限公司 用免疫刺激剂治疗癌症

Also Published As

Publication number Publication date
CA2708229A1 (en) 2009-06-18
JP2011506473A (ja) 2011-03-03
AR069769A1 (es) 2010-02-17
US20100267637A1 (en) 2010-10-21
EP2240194A4 (en) 2011-12-21
AU2008335025A1 (en) 2009-06-18
EP2240194A1 (en) 2010-10-20
WO2009076587A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
Savarese et al. Prevention of chemotherapy and radiation toxicity with glutamine
Klimberg et al. Glutamine, cancer, and its therapy
Ziegler et al. Effects of Glutamine Supplementation on Circulating Lymphocytes AfterBone Marrow Transplantation: A Pilot Study
JP2005518361A (ja) 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物
Xue et al. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor
US20100317583A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2021164706A1 (zh) 包含亚甲蓝类染料的药物组合物及其应用
JP2023544310A (ja) プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物
Jacobs Use of Methotrexate and 5-FU for Recurrent Head and Neck Cancer¹
CN101945664A (zh) 用α胸腺肽和激酶抑制剂的组合治疗黑素瘤
CN119405790A (zh) 胰酶联合灵芝在制备治疗白细胞减少的药物中的用途
RU2159116C1 (ru) Способ активационной терапии заболеваний
CN103202861A (zh) 酪酸梭菌、双歧杆菌二联活菌制剂与抗癌药物组合在制备治疗肠癌药物中的应用
CN117045687A (zh) 一种凝结芽孢杆菌在制备防治电离辐射致肠道损伤的药物中的应用
CN102125558A (zh) 一种复方左亚叶酸钠氟尿嘧啶抗肿瘤药
KR20210039414A (ko) 암의 치료를 위한 병용 요법
CN102716465B (zh) 治疗肿瘤的药物组合物及其制备方法
KR20210039413A (ko) 암의 치료를 위한 병용 요법
US20130079416A1 (en) Homeopathic medicament comprising phenacetin for the treatment of cancer
CN120037233A (zh) 迷迭香酸和青藤碱在协同治疗疾病中的应用
CN105816862A (zh) 乌司他丁在制备治疗前列腺癌药物中的用途
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
CN106039297B (zh) 含乌司他丁的药物组合物在制备治疗食管癌药物中的用途
KR100835607B1 (ko) 감마-폴리글루탐산을 유효성분으로 함유하는 해수 질환의완화 및 치료제용 약학적 조성물
CN1672691A (zh) 鱿鱼墨汁提取物的制备及其用于制造预防和治疗人类肿瘤的药物及食品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110112